This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
Scientific Reports Open Access 16 October 2019
-
Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
Leukemia Open Access 29 October 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327: 1345–1350.
Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26: 2326–2335.
Andhavarapu S, Roy V . Immunomodulatory drugs in multiple myeloma. Expert Rev Hematol 2013; 6: 69–82.
Adès L, Fenaux P . Immunomodulating drugs in myelodysplastic syndromes. Am Soc Hematol Educ Program 2011; 2011: 556–560.
List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.
Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86–93.
Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771–4779.
Broyl A, Kuiper R, van Duin M, van der Holt B, El Jarari L, Bertsch U et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013; 121: 624–627.
Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958–965.
Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765–3776.
Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R et al. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood 2012; 120: 3419–3424.
Gandhi AK, Avet-Loiseau H, Waldman M, Thakurta A, Aukerman SL, Chen G et al. Detection and quantification of cereblon protein and mRNA in multiple myeloma cell lines and primary CD138+multiple myeloma cells. ASH 2012; (abstract #4043).
Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008; 5: e35.
Sugimoto Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A et al. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol 2012; 5: 4.
Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene 2013; 32: 1110–1120.
Acknowledgements
This work was supported by the Direction régionale de la recherche clinique Assistance-Publique Hôpitaux de Paris (PHRC MDS-04). We thank Raphael Petit and Rosa Sapena for collecting clinical data, and Morgane Bourmaud and Audrey Gauthier for technical assistance.
Authors contributions
VS, SK, VC and CL performed the experiments; AR performed all statistical analysis; LA, VS, SP, AT, PF, FD provided samples; PF, MF, OK wrote the paper; OK conceived and was responsible for the study design.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
VS is consultant for Celgene, Janssen and Novartis. PF is consultant for Celgene, Ortho Biotech, Roche, Novartis, Cephalon, Epicept, Amgen, and Merck. FD is consultant for Novartis. MF is consultant for Celgene
Rights and permissions
About this article
Cite this article
Sardnal, V., Rouquette, A., Kaltenbach, S. et al. A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia 27, 1610–1613 (2013). https://doi.org/10.1038/leu.2013.59
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.59
This article is cited by
-
Cereblon expression is a prognostic marker in newly diagnosed POEMS syndrome treated with lenalidomide plus dexamethasone
Annals of Hematology (2021)
-
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
Scientific Reports (2019)
-
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
Leukemia (2016)
-
8-year-sustained response in a patient with isolated del(5q) myelodysplastic syndrome undergoing continuous treatment with lenalidomide: a case report
memo - Magazine of European Medical Oncology (2016)
-
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
Leukemia (2016)